Jazz Pharmaceuticals

News

Servier snaps up cancer biotech Day One in $2.5bn deal

Servier has made a takeover offer for Day One and its fast-growing glioma therapy Ojemda, as it pitches to drive sales above €10bn by 2030.

News

Jazz, Roche combo cleared by FDA for lung cancer

Can FDA approval of Jazz Pharma's Zepzelca in a combination regimen for extensive-stage small cell lung cancer return sales of the drug to growth?

News

Sand picture of balloons as brains, flown by man and child

Jazz gets FDA okay for Chimerix brain cancer drug

Jazz Pharmaceuticals has become the first drugmaker to get FDA approval for a treatment for diffuse midline glioma with H3 K27M mutations.

News

ASCO 25: Jazz, PharmaMar reveal SCLC survival data

Jazz and PharmaMar have revealed the overall survival data with their small-cell lung cancer drug Zepzelca, described as a 'milestone' in the disease.

News

Dyvyzat box, bottle, and oral delivery mechanism.

Italfarmaco closes on EU okay for Duchenne drug

Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular dystrophy (DMD).

News

Jazz pays $145m to resolve Xyrem antitrust disputes

Jazz Pharma has offered to pay $145m to settle claims it paid to prevent generic versions of its narcolepsy drug Xyrem from reaching the US market.

Servier snaps up cancer biotech Day One in $2.5bn deal

Jazz, Roche combo cleared by FDA for lung cancer

Jazz gets FDA okay for Chimerix brain cancer drug

ASCO 25: Jazz, PharmaMar reveal SCLC survival data

Italfarmaco closes on EU okay for Duchenne drug

Jazz pays $145m to resolve Xyrem antitrust disputes

Recordati gets €10.9bn takeover bid from private equity firm

Using AI-driven synthetic personas to take your insights fur...

Jazz Pharmaceuticals

Editor's Picks